NCT00214955已完成3 期
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Neuropathic Pain
Cephalon32 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2005年9月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 120
- 试验地点
- 32
研究概览
简要总结
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Neuropathic Pain
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients are included in the study if all of the following criteria are met:
- •The patient is willing to provide written informed consent to participate in this study.
- •The patient is 18 through 80 years of age.
- •Women must be surgically sterile, 2 years postmenopausal, or, if of childbearing potential, using a medically accepted method of birth control (ie, barried method with spermicide, steroidal contraceptive [oral, transdermal, implanted, or injected contraceptives must be used in conjunction with a barrier method], or intrauterine device [IUD]) and agree to continued use of this method for the duration of the study.
- •The patient has chronic neuropathic pain of at least 3 months duration associated with any of the following conditions: diabetic peripheral neuropathy, postherpetic neuralgia, traumatic injury, or complex regional pain syndrome. Patients with other neuropathic pain etiologies may qualify for the study with permission from the Cephalon medical monitor or designee.
- •The patient is currently using 1 of the following: at least 60 mg of oral morphine/day, or at least 25 mcg transdermal fentanyl/hour, or atleast 30 mg or oxycodone/day, or at least 8 mg hydromorphone/day, or an equianalgesic dose of another opioid/day as a stable dose of around-the-close (ATC) therapy for at least the previous 7 days before enrollment in the study.
- •The patient reports an average pain intensity (PI) score, over the prior 24 hours, of less than 7 (0=no pain through 10=worst pain) for their chronic neuropathic pain.
- •The patient experiences, on average, 1 to 4 BTP episodes (defined as temporary flares of sever or excruciating pain) per day while taking ATC opioid therapy, and on average, the duration of each BTP episode is less than 4 hours.
- •The patient currently uses opioid therapy for alleviation of BTP episodes, occuring at the location of the chronic pain, and achieves at least partial relief.
- •The patient is able to effectively self-administer the study drug.
排除标准
- •Patients are excluded from participating in this study if 1 or more of the following criteria are met:
- •The patient has uncontrolled or rapidly escalating pain as determined by the investigator (ie, the ATC therapy may be expected to change between the first and last treatments with study drug), or has pain uncontrolled by therapy that could adversely impact the safety of the patient or that could be compromised by treatment with study drug.
- •The patient has known or suspected hypersensitivities, allergies, or other contraindications to any ingredient in the study drug.
- •The patient has a recent history (within 5 years) or current evidence of alcohol or other substance abuse.
- •The patient has cardiopulmonary disease that would, in the opinion of the investigator, significantly increase the risk of treatment with potent synthetic opioids.
- •The patient has medical or psychiatric disease that, in the opinion of the investigator, would compromise collected data.
- •The patient is expected to have surgery during the study and it is anticipated that the surgery will alleviate the patient's pain.
- •The patient has had therapy before study drug treatment that, in the opinion of the investigator, could alter pain or response to pain medication.
- •The patient is pregnant or lactating.
- •The patient has participated in a previous study with ORAVESCENT fentanyl.
- •The patient has participated in a study involving an investigational drug in the previous 30 days.
- •The patient has received a monoamine oxidase inhibitor (MAOI) within 14 days before the first treatment with study drug.
- •The patient has any other medical condition or is receiving concomitant medication/therapy (eg, regional nerve block) that would, in the opinion of the investigator, compromise the patient's safety or compliance with the study protocol, or compromise collected data.
- •The patient is involved in active litigation in regard to their chronic pain.
- •The patient has a positive urin screen (UDS) for a medication not prescribed by their physician or no reasonable explanation can be provided to the Cephalon medical monitor.
研究者
研究点 (32)
Loading locations...
相似试验
已完成
3 期
Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough PainChronic Low Back PainNCT00214942Cephalon
已完成
2 期
Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA)Geographic AtrophyNCT01782989Paul Yates, MD, PhD286
进行中（未招募）
2 期
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary FibrosisPulmonary Fibrosis Secondary to Systemic SclerosisPulmonary Fibrosis, Interstitial Lung DiseaseInterstitial Lung Disease Due to Connective Tissue Disease (Disorder)Interstitial Lung Disease in Patients With Rheumatoid ArthritisInterstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified ElsewhereInterstitial Lung Disease With Systemic SclerosisPulmonary FibrosisHypersensitivity PneumonitisInterstitial Lung DiseaseNCT06329401Avalyn Pharma Inc.375
尚未招募
3 期
A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.Type 2 Diabetes MellitusNCT06731075Oramed, Ltd.300
进行中（未招募）
2 期
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA VaccineCOVID-19NCT05636319Suzhou Abogen Biosciences Co., Ltd.14,168